Neuroprotective and hepatoprotective effects of micronized purified flavonoid fraction (Daflon Ŵ) in lipopolysaccharide-treated rats

Drug Discoveries & Therapeutics

Volumn 6, Issue 6, 2011, Pages 306-314

  Abdel Salam, Omar ^a   Youness, Eman ^a   Mohammed, Nadia ^a   Abd Elmoniem, Mehrevan ^a   Omara, Enayat ^a   Sleem, Amany ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Flavonoid fraction; lipopolysaccharide; oxidative stress

Indexed keywords

EID: 85008733152     PISSN: 18817831     EISSN: 1881784X     Source Type: Journal    
DOI: 10.5582/ddt.2012.v6.6.306     Document Type: Article

References (47)

1. Katsenis K. Micronized purified flavonoid fraction (MPFF): A review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol. 2005; 3:1-9.
2. Jiang ZM, Cao JD. The impact of micronized purified flavonoid fraction on the treatment of acute hemorrhoidal episodes. Curr Med Res Opin. 2006; 22:1141-1147.
3. Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: An update of the available evidence. Curr Vasc Pharmacol. 2009; 7:303-308.
4. Jantet G. Chronic venous insufficiency: Worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized Flavonoids. Angiology. 2002; 53:245-256.
5. Sirlak M, Akar AR, Eryilmaz S, Cetinkanat EK, Ozcinar E, Kaya B, Elhan AH, Ozyurda U. Micronized purified flavonoid fraction in pretreating CABG patients. Tex Heart Inst J. 2010; 37:172-177.
6. Friesenecker B, Tsai AG, Intaglietta M. Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Int J Microcirc Clin Exp. 1995; 15 (Suppl 1):17-21.
7. Cyrino FZ, Bottino DA, Lerond L, Bouskela E. Micronization enhances the protective effect of purified flavonoid fraction against post ischaemic microvascular injury in the hamster cheek pouch. Clin Exp Pharmacol Physiol. 2004; 31:159-162.
8. Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol. 2008; 27:81-85.
9. Delbarre B, Delbarre G, Calinon F. Effect of Daflon 500 mg, a flavonoid drug, on neurological signs, levels of free radicals and electroretinogram in the gerbil after ischemia-reperfusion injury. Int J Microcirc Clin Exp. 1995; 15 (Suppl. 1):27-33.
10. Rapavi E, Kocsis I, Fehér E, Szentmihályi K, Lugasi A, Székely E, Blázovics A. The effect of citrus flavonoids on the redox state of alimentary-induced fatty liver in rats. Nat Prod Res. 2007; 21:274-281.
11. Quan N, Stern EL, Whiteside MB, Herkenham M. Induction of proinflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol. 1999; 93:72-80.
12. Turrin NP, Gayle D, Ilyin SE, Flynn MC, Langhans W, Schwartz GJ, Plata-Salaman CR. Proinflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull. 2001; 54:443-453.
13. Halliwell B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging. 2001; 18:685-716.
14. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol. 2005; 18:315-321.
15. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007; 55:453-462.
16. Paget GE, Barnes JM. Toxicity testing. In: Evaluation of Drug Activities Pharmacometics (Laurence DR, Bacharach AL, eds.). Academic, London, UK, 1964; pp. 1-135.
17. Vona-Davis L, Wearden P, Hill J, Hill R. Cardiac response to nitric oxide synthase inhibition using aminoguanidine in a rat model of endotoxemia. Shock. 2002; 17:404-410.
18. Beurel E, Jope RS. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation. 2009; 11:6-9.
19. Ruiz-Larrea MB, Leal AM, Liza M, Lacort M, de Groot H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids. 1994; 59:383-388.
20. Ellman GL. Tissue sulfhydryl groups. Arch Biochem. 1959; 82:70-77.
21. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determination in plasma: A critical evaluation. Clin Chem. 1995; 41:892-896.
22. Higashino K, Takahashi Y, Yamamura Y. Release of phenyl acetate esterase from liver microsomes by carbon tetrachloride. Clin Chim Acta. 1972; 41:313-320.
23. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995; 96:2882-2891.
24. Crowley LV. The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin Chem. 1967; 13:482-487.
25. Belfield A, Goldberg DM. Human serum glucose-6 phosphatase activity: Confirmation of its presence and lack of diagnostic value. Clin Chim Acta. 1971; 31:8185.
26. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem. 1995; 41:18191828.
27. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43:109-142.
28. Wang W, Ballatori N. Endogenous glutathione conjugates: Occurrence and biological functions. Pharmacol Rev. 1998; 50:335-356.
29. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9:46-56.
30. Marques F, Falcao AM, Sousa JC, Coppola G, Geschwind D, Sousa N, Correia-Neves M, Palha JA. Altered iron metabolism is part of the choroid plexus response to peripheral inflammation. Endocrinology. 2009; 150:2822-2828.
31. Spencer SJ, Mouihate A, Pittman QJ. Peripheral inflammation exacerbates damage after global ischemia independently of temperature and acute brain inflammation. Stroke. 2007; 38:1570-1577.
32. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D. LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation. 2010; 7:56.
33. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals and brain aging. Clin Geriatr Med. 2004; 20:329-359.
34. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain. 2011; 134:1914-1924.
35. Behrens MM, Sejnowski TJ. Does schizophrenia arise from oxidative dysregulation of parvalbumin interneurons in the developing cortex? Neuropharmacology. 2009; 57:193-200.
36. Galea E, Reis DJ, Feinstein DL. Cloning and expression of inducible nitric oxide synthase from rat astrocytes. J Neurosci Res. 1994; 37:406-414.
37. Duval DL, Miller DR, Collier J, Billings RE. Characterization of hepatic nitric oxide synthase: Dentification as the cytokine-inducible form primarily regulated by oxidants. Mol Pharmacol. 1996; 50:277-284.
38. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6:99-104.
39. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 2003; 199:221228.
40. Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta. 2005; 352:37-47.
41. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K, Hashimoto K. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 2003; 72:2877-2885.
42. Kotur-Stevuljevic J, Spasic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Stefanovic A, Vujovic A, Memon L, Kalimanovska-Ostric D. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem. 2008; 41:1067-1073.
43. Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J. Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002; 48:261-268.
44. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H. Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler. 2009; 15:399402.
45. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 1998; 139:307-315.
46. Abdel-Salam OME, Khadrawy YA, Mohammed NA. Neuroprotective effect of nitric oxide donor isosorbide-dinitrate against oxidative stress induced by ethidium bromide in rat brain. EXCLI J. 2012; 11:125-141.
47. Meyer O. Safety of use of Daflon 500 mg confirmed by acquired experience and new research. Phlebology. 1992; 7 (Suppl 2):64-68.